Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix to Fund European Cancer Studies Using Microarrays

NEW YORK (GenomeWeb News) — Affymetrix is launching a program to fund microarray-related cancer research at European research centers, the company said today.
Under the Collaborations in Cancer Research Program, Affymetrix said it will financially support “selected research projects” that use a variety of microarray-based applications and that are aimed at developing new understanding and discoveries in 10 types of cancer.
The research is being performed at a number of academic and state-run research facilities throughout Europe.
The company said these programs use microarray applications, including copy number analysis, gene expression, chromatin immunoprecipitation, and splicing pattern analysis.
Affy also said it will help researchers “obtain tools and training,” and said it will “provide forums where investigators can exchange knowledge and share best practices.”
Researchers in the programs are studying leukemia and cancers of the breast, lung, prostate, thyroid, skin, and other organs.
Affy said results of these studies will be presented at a meeting it will sponsor later this year. The company also plans to expand the program in 2007 to include research facilities in Japan and North America.
A partial list of CCRP participants can be found here.
The company did not say how much financial support it will offer these programs.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.